MX2017002892A - Composiciones y metodos para tratar trastornos de proliferacion. - Google Patents

Composiciones y metodos para tratar trastornos de proliferacion.

Info

Publication number
MX2017002892A
MX2017002892A MX2017002892A MX2017002892A MX2017002892A MX 2017002892 A MX2017002892 A MX 2017002892A MX 2017002892 A MX2017002892 A MX 2017002892A MX 2017002892 A MX2017002892 A MX 2017002892A MX 2017002892 A MX2017002892 A MX 2017002892A
Authority
MX
Mexico
Prior art keywords
methods
phenyl
pyridin
aminocyclobutyl
amine
Prior art date
Application number
MX2017002892A
Other languages
English (en)
Inventor
Jean-Marc Lapierre
T Dransfield Daniel
Eathiraj Sudharshan
Schwartz Biran
Yu Yi
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MX2017002892A publication Critical patent/MX2017002892A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a métodos para tratar trastornos proliferativos celulares, tales como cáncer o síndrome de Proteus, usando (3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3H-imíd azo[4,5-b]píridin-2-íl)piridin-2-amina) o 3-(3-(4-(1-aminociclobut il)fenil)-5-(3-morfolinofenil)-3H-imidazo[4,5-b]piridin-2-il)piri din-2-amina o N-(1-(3-(3-(4-(1-aminociclobutil)fenil)-2-(2-aminopi ridin-3-il)-3H-imidazo[4,5-b]piridin-5-il)fenil)piperidin-4-il)-N -metilacetamida; los métodos de la presente invención pueden referirse también a métodos para tratar trastornos proliferativos celulares, tales como cáncer o síndrome de Proteus, usando los compuestos anteriores en combinación con ((R)-6-(2-fluorofenil)-N- (3-(2-((2-metoxietil)amino)etil)fenil)-5,6-dihidrobenzo[h]quinazo lin-2-amina).
MX2017002892A 2014-09-05 2015-09-04 Composiciones y metodos para tratar trastornos de proliferacion. MX2017002892A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046502P 2014-09-05 2014-09-05
US201462082236P 2014-11-20 2014-11-20
PCT/US2015/048520 WO2016037044A1 (en) 2014-09-05 2015-09-04 Compositions and methods for treating proliferation disorders

Publications (1)

Publication Number Publication Date
MX2017002892A true MX2017002892A (es) 2017-06-06

Family

ID=55436479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002892A MX2017002892A (es) 2014-09-05 2015-09-04 Composiciones y metodos para tratar trastornos de proliferacion.

Country Status (14)

Country Link
US (1) US9949981B2 (es)
EP (1) EP3189036B1 (es)
JP (2) JP6574245B2 (es)
KR (1) KR20170045748A (es)
CN (2) CN107074769B (es)
AU (2) AU2015311751B2 (es)
BR (1) BR112017004459A2 (es)
CA (1) CA2958770A1 (es)
ES (1) ES2955926T3 (es)
IL (2) IL250715B (es)
MX (1) MX2017002892A (es)
RU (2) RU2711500C2 (es)
SG (1) SG11201701704XA (es)
WO (1) WO2016037044A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11561226B2 (en) 2016-03-14 2023-01-24 Pierce Biotechnology Inc. Detection and quantification of AKT-mTOR pathway proteins
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
EP3576729A4 (en) * 2017-02-02 2021-04-14 Epizyme, Inc. CANCER TREATMENT MODALITIES
WO2019071171A1 (en) * 2017-10-05 2019-04-11 The Board Of Trustees Of The University Of Illinois PROCESS FOR TREATING DREPANOCYTOSIS
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
JP2022507495A (ja) * 2018-11-16 2022-01-18 アーキュール・インコーポレイテッド 癌治療のための医薬の組合せ
WO2020181009A1 (en) * 2019-03-04 2020-09-10 Northwestern University Bacterial enzymatic conversion of anthracyclie chemotherapeutics
WO2022053708A1 (en) * 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
KR20230079113A (ko) * 2020-09-30 2023-06-05 치아타이 티안큉 파마수티컬 그룹 주식회사 Akt 키나아제 억제제로서의 화합물
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2748174A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
BRPI0923786C8 (pt) * 2008-12-30 2021-05-25 Arqule Inc compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
US8049005B2 (en) * 2009-03-31 2011-11-01 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepine compounds
DK2519522T3 (en) * 2009-12-30 2014-12-08 Arqule Inc SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS
CN103748093B (zh) 2011-06-24 2016-06-01 艾科尔公司 被取代的咪唑并吡啶基-氨基吡啶化合物
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds

Also Published As

Publication number Publication date
EP3189036A4 (en) 2018-04-04
JP2017526698A (ja) 2017-09-14
WO2016037044A1 (en) 2016-03-10
KR20170045748A (ko) 2017-04-27
CN111494378A (zh) 2020-08-07
RU2017111204A (ru) 2018-10-05
IL277028A (en) 2020-10-29
CA2958770A1 (en) 2016-03-10
RU2711500C2 (ru) 2020-01-17
AU2020203706A1 (en) 2020-06-25
BR112017004459A2 (pt) 2017-12-05
JP6574245B2 (ja) 2019-09-11
AU2015311751B2 (en) 2020-03-12
AU2020203706B2 (en) 2022-01-13
IL250715B (en) 2020-09-30
JP2020002148A (ja) 2020-01-09
JP6837525B2 (ja) 2021-03-03
AU2015311751A1 (en) 2017-03-09
EP3189036B1 (en) 2023-07-19
US9949981B2 (en) 2018-04-24
CN107074769B (zh) 2020-04-07
RU2017111204A3 (es) 2019-03-25
ES2955926T3 (es) 2023-12-11
SG11201701704XA (en) 2017-04-27
IL250715A0 (en) 2017-04-30
EP3189036A1 (en) 2017-07-12
CN107074769A (zh) 2017-08-18
RU2019142694A (ru) 2020-02-26
US20160067260A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
MX2017002892A (es) Composiciones y metodos para tratar trastornos de proliferacion.
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
PH12016501388A1 (en) Heteroaryls and uses thereof
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
EA201790657A1 (ru) Хинолиноновые производные пиридин-2(1h)-она как ингибиторы мутантной изоцитратдегидрогеназы
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
DK3357922T3 (da) 2-((5-(1-(3-(methylsulfonyl)propyl)piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8h)-on-derivater og relaterede forbindelser som cdk4-inhibitorer til behandling af tumorer
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
NZ603456A (en) 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
MX2015014944A (es) Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer.
WO2011101069A3 (en) 1, 8 -naphthyridines as kinase inhibitors
MX2017000521A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
MX2021009117A (es) Pirazolopiridinas y triazolopiridinas como inhibidores receptores de adenosina a2a / a2b.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
IL284266A (en) History of (pyridin-2-yl)amine as an inhibitor of TGF-β in cell R1 (ALK5) for cancer treatment
MX2017000522A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
MX2022000794A (es) Derivados de 4-(imidazo[1,2-a]piridin-3-il)pirimidina.